Replimune REPL 深 滬
等待開盤 01-29 09:30:00 美东时间
7.36
-0.170
-2.26%
華盛通- 最 高7.6181
- 今 開7.52
- 成交量 72.98万股
- 最 低 7.30
- 昨 收 7.53
- 總市值 5.74亿
- 52周最高 14.7952
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 2.68
- 委 比 88.59%
- 總股本 7805.58万
- 歷史最高 54.79
- 量 比 0.45
- 振 幅 4.22%
- 歷史最低 2.68
- 每 手 1
- 風險率 2.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference
Replimune Group ( ($REPL) ) has shared an announcement. On January 12, 2026, Re...
01-12 21:43
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 1:30 PM PT. The presentation will be webcast live and available for replay for 30 days on Replimune’s website. Replimune, headquartered in Woburn, MA, specializes in pioneering novel oncolytic immunotherapies using its RPx platform based on a HSV-1 backbone to induce systemic anti-tumor immune response...
2025-12-18 13:00
SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
2025-11-27 04:13
Replimune Group Q2 EPS $(0.90) Misses $(0.74) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.74) by 21.46 percent. This is a 32.35 percent decrease over losses of $(0.68) per share from
2025-11-06 21:21
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Replimune Group announced the acceptance of the BLA resubmission for RP1 for advanced melanoma with a PDUFA target date of April 10, 2026. RP1's Phase 3 trial, IGNYTE-3, continues to enroll patients, with promising data showing an ORR of 44% in acral melanoma and strong responses across multiple NMSC types. RP2's Phase 2/3 REVEAL trial for metastatic uveal melanoma is actively enrolling. The company reported a cash balance of $323.6 million and a...
2025-11-06 13:00
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
2025-11-03 21:14
BMO Capital Upgrades Replimune Group to Market Perform, Raises Price Target to $11
BMO Capital analyst Evan David Seigerman upgrades Replimune Group (NASDAQ:REPL) from Underperform to Market Perform and raises the price target from $2 to $11.
2025-11-03 18:37
期权扫描 | 高通期权成交放量超8倍，一CALL单飙升2680%；ASST获多张CALL单押注看涨
高通推出人工智能芯片，股价飙升！期权成交放量超8倍，一CALL单飙升2680%；ASST获多张CALL单押注看涨至3美元>>
2025-10-28 17:10
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
2025-10-28 10:08
